OBJECTIVES: Hypoglycemia is one of the major limiting factors in the management of T2DM patients on insulin. Disutility for different types of hypoglycemic events is an important component of cost-utility analysis. The aim of this study was to determine disutility for mild, severe and nocturnal hypoglycemic events in T2DM patients receiving insulin therapy. METHODS: One thousand T2DM patients on insulin (mean age – 61.1 yrs; male/female – 265/735) were included in the real-world study aimed to measure their quality of life and hypoglycemia burden. All the patients completed SF-36 questionnaire. To determine the utility value for each patient SF-6D questionnaire based on the SF-36 was used. In total, 631 patients recorded episodes of hypoglycemia during the last month. The patients without hypoglycemia and patients with mild, severe or nocturnal hypoglycemic events were analyzed. The average utility value for each group was calculated with adjustment for gender, age, comorbidities, late complications, glycosylated hemoglobin level. The disutility for one episode of each type of hypoglycemia was determined as the difference between the average utility for patients without hypoglycemia and average utility for patients with corresponding type of hypoglycemia. RESULTS: The utility value for patients without hypoglycemia was 0.680; for patients with mild hypoglycemia – 0.668; for patients with severe hypoglycemia – 0.595; for patients with nocturnal hypoglycemic event – 0.657. Patients without hypoglycemia had the highest utility value whereas patients with severe hypoglycemia the lowest one. Disutility value for mild hypoglycemic event was 0.012, severe event – 0.085, and nocturnal hypoglycemic event – 0.023. CONCLUSIONS: The values of health utility and disutility for T2DM patients receiving insulin therapy were obtained from the real-world data. Severe hypoglycemia was associated with greater disutility than non-severe and nocturnal hypoglycemia. The obtained values of health utility and disutility may be used in cost-utility analysis to estimate treatment outcomes for T2DM.